pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Samsca
drug
save

Samsca

Marketedupdated 6mo ago
by Otsuka America Pharmaceutical Inc
Approved
community read0 votes

🐶 often sniffed alongside

top 3
  • tagApproval2 co-mentions · 1 sources
  • tagSmall Molecule1 co-mentions · 1 sources
  • drugTOLVAPTAN1 co-mentions · 1 sources

all catalysts(0)

nothing on the calendar yet

Trials studying Samsca

  • phase3A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)recruitingn=20
  • phase3A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)withdrawn
  • —Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKDcompletedn=1,802
  • phase1A Study of HRS-9057 in Patients With Heart Failure and Volume Overloadcompletedn=25
  • phase1Phase I Study Multi Dose of 7.5mg Tolvaptan in Health Malecompletedn=12
  • phase1Single Dose of 7.5mg Tolvaptan Phase I Clinical Trial Protocolcompletedn=10
  • —Samsca PMS in ADPKD Patientscompletedn=2,067
  • phase2A Phase 2 Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremiacompletedn=241

News(2)

  • Biogen-backed Estuary nabs $93M for kidney disease gene therapy
    The Series A round, which was led by RA Capital, will help fund the development of two genetic medicines designed to treat an inherited kidney disorder known as "ADPKD."
    biopharma_dive · 1mo ago
  • Estuary flows out of stealth with $103M to propel kidney disease gene therapies into clinic
    Estuary Biotherapeutics has swum out of stealth with $103 million in funding to power a pair of gene therapies into clinical trials for an inherited kidney disorder.
    fiercebiotech · 1mo ago
brand
Samsca
generic
tolvaptan
indication
Hyponatremia
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 4h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?